blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2531463

EP2531463 - HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.09.2018
Database last updated on 28.09.2024
FormerThe patent has been granted
Status updated on  29.09.2017
FormerGrant of patent is intended
Status updated on  22.09.2017
FormerExamination is in progress
Status updated on  01.09.2017
FormerGrant of patent is intended
Status updated on  11.04.2017
FormerExamination is in progress
Status updated on  08.11.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Université de Nantes
1, quai de Tourville
44000 Nantes / FR
For all designated states
CHU Nantes
5 allée de l'Ile Gloriette
44093 Nantes Cedex 1 / FR
[2017/44]
Former [2012/50]For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Université de Nantes
1, quai de Tourville
44000 Nantes / FR
For all designated states
Chu Nantes
5 allée de l'Ile Gloriette
44093 Nantes Cedex 1 / FR
Inventor(s)01 / GESTIN, Jean-François
Unité Inserm 892 Institut De Recherche
Therapeutique
8 Quai Moncousu - BP70721
F-44007 Nantes Cedex 1 / FR
02 / GUERARD, François
Unité Inserm 892 Institut De Recherche
Therapeutique
8 Quai Moncousu - BP70721
F-44007 Nantes Cedex 1 / FR
03 / FAIVRE-CHAUVET, Alain
Unité Inserm 892 Institut De Recherche
Therapeutique
8 Quai Moncousu - BP70721
F-44007 Nantes Cedex 1 / FR
 [2012/50]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[2017/44]
Former [2012/50]Jacobson, Claude
Cabinet Lavoix
2, Place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Application number, filing date11703417.302.02.2011
[2017/44]
WO2011EP51480
Priority number, dateEP2010030511003.02.2010         Original published format: EP 10305110
[2012/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011095517
Date:11.08.2011
Language:EN
[2011/32]
Type: A1 Application with search report 
No.:EP2531463
Date:12.12.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 11.08.2011 takes the place of the publication of the European patent application.
[2012/50]
Type: B1 Patent specification 
No.:EP2531463
Date:01.11.2017
Language:EN
[2017/44]
Search report(s)International search report - published on:EP11.08.2011
ClassificationIPC:C07D347/00, C07C213/00, C07C213/02, C07D421/12, C07F7/22, C07B59/00
[2017/18]
CPC:
C07B59/002 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P35/04 (EP); C07C213/00 (EP,US); C07C213/02 (EP,US);
C07D347/00 (EP,US); C07D421/12 (EP,US); C07F7/2208 (EP,US) (-)
C-Set:
C07C213/00, C07C215/68 (EP,US);
C07C213/00, C07C217/48 (US,EP);
C07C213/02, C07C215/68 (US,EP);
C07C213/02, C07C217/48 (US,EP)
Former IPC [2012/50]C07B59/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/50]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:Radioaktive Hypervalenzastatin- oder -iodinverbindungen und Herstellungsverfahren dafür[2017/18]
English:HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF[2012/50]
French:Composés d'astate ou d'iode radioactif hypervalent et procédés de préparation correspondants[2017/18]
Former [2012/50]RADIOAKTIVE HYPERVALENZASTATIN- ODER -IODINVERBINDUNGEN UND HERSTELLUNGSVERFAHREN DAFÜR
Former [2012/50]COMPOSÉS HYPERVALENTS D'ASTATINE OU D'IODE RADIOACTIF, ET LEURS PROCÉDÉS DE PRÉPARATION
Entry into regional phase25.07.2012National basic fee paid 
25.07.2012Designation fee(s) paid 
25.07.2012Examination fee paid 
Examination procedure25.07.2012Amendment by applicant (claims and/or description)
25.07.2012Examination requested  [2012/50]
26.06.2013Despatch of a communication from the examining division (Time limit: M06)
19.12.2013Reply to a communication from the examining division
07.04.2014Despatch of a communication from the examining division (Time limit: M04)
06.08.2014Reply to a communication from the examining division
29.07.2015Despatch of a communication from the examining division (Time limit: M06)
29.01.2016Reply to a communication from the examining division
08.07.2016Despatch of a communication from the examining division (Time limit: M06)
21.12.2016Reply to a communication from the examining division
12.04.2017Communication of intention to grant the patent
10.08.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.08.2017Fee for grant paid
10.08.2017Fee for publishing/printing paid
22.09.2017Information about intention to grant a patent
22.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.06.2013
Opposition(s)02.08.2018No opposition filed within time limit [2018/41]
Fees paidRenewal fee
27.02.2013Renewal fee patent year 03
24.02.2014Renewal fee patent year 04
24.02.2015Renewal fee patent year 05
25.02.2016Renewal fee patent year 06
23.02.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.02.2011
AL01.11.2017
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
MK01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
MT02.02.2018
BE28.02.2018
IS01.03.2018
[2020/33]
Former [2020/31]HU02.02.2011
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
MK01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
MT02.02.2018
BE28.02.2018
IS01.03.2018
Former [2020/27]HU02.02.2011
AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
PT01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
MT02.02.2018
BE28.02.2018
IS01.03.2018
Former [2020/16]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
TR01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
MT02.02.2018
BE28.02.2018
IS01.03.2018
Former [2020/08]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
MT02.02.2018
BE28.02.2018
IS01.03.2018
Former [2019/12]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
BE28.02.2018
IS01.03.2018
Former [2019/09]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IE02.02.2018
LU02.02.2018
IS01.03.2018
Former [2018/52]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SI01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
LU02.02.2018
IS01.03.2018
Former [2018/44]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
MC01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/40]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
RO01.11.2017
RS01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/39]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
IT01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
RS01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/37]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
PL01.11.2017
RS01.11.2017
SE01.11.2017
SK01.11.2017
SM01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/35]AT01.11.2017
CY01.11.2017
CZ01.11.2017
DK01.11.2017
EE01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
RS01.11.2017
SE01.11.2017
SK01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/24]AT01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
LV01.11.2017
NL01.11.2017
RS01.11.2017
SE01.11.2017
BG01.02.2018
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/23]AT01.11.2017
ES01.11.2017
FI01.11.2017
HR01.11.2017
LT01.11.2017
NL01.11.2017
RS01.11.2017
SE01.11.2017
NO01.02.2018
GR02.02.2018
IS01.03.2018
Former [2018/22]ES01.11.2017
FI01.11.2017
LT01.11.2017
NL01.11.2017
NO01.02.2018
Cited inInternational search[A]  - C.C. HUANG ET AL., "Potential organ- or tumor-imaging agents. 18. radionated diamines and bisquaternaries", J. MED. CHEM., (1979), vol. 22, no. 4, pages 449 - 452, XP002588552 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm00190a018
by applicant   - ZALUTSKY MR; VAIDYANATHAN G, CURR PHARM DES., (2000), vol. 6, pages 1433 - 1455
    - ZALUTSKY MR; PRADEEP K. GARG; HENRY S. FRIEDMAN; DARELL D. BIGNER, PROC. NATL. ACAD. SCI. U.S.A, (1989), vol. 86, pages 7149 - 7153
    - WILBUR DS; CHYAN MK; HAMLIN DK; PERRY MA., BIOCONJUGATE CHEM., (2009), vol. 20, pages 591 - 602
    - PRUSZYNSKI M; BILEWICZ A; ZALUTSKY MR, BIOCONJUGATE CHEM., (2007), vol. 19, pages 958 - 965
    - MACKLIS MR, INT. J. RADIATION ONCOLOGY BIOL. PHYS., (2006), vol. 66, pages S30 - S34
    - MEREDITH MR ET AL., J. NUCL. MED., (1995), vol. 36, pages 2229 - 2233
    - BOURGUIGNON MH; PAUWELS EKJ; LOC'H C; MAZIERE B, EUR. J. NUCL. MED., (1997), vol. 24, pages 331 - 344
    - PENTLOW KS ET AL., J. NUCL. MED., (1996), vol. 37, pages 1557 - 1562
    - J. MARCH, Advanced Organic Chemistry, MCGRAW HILL BOOK COMPANY, (1977), pages 251 - 259
    - AMEY RL; MARTIN JC, J. ORG. CHEM., (1979), vol. 44, pages 1779 - 1784
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.